6 registrations that name petrelintide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
8US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 6 registrations
RecruitingNCT07843498
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
Phase 3
Hoffmann-La Roche
About 3,900 people
Started Sep 30, 2026
In plain words A Phase 3 study of petrelintide in people 18 and older, run by Hoffmann-La Roche. It plans to enroll about 3,900 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity or Overweight.
Participants with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity
History of at least one self-reported unsuccessful dietary effort to lose body weight
The exclusion criteria are on the listing.
What it tests, as registered
Petrelintide; Placebo
Registered summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).
Where, as registered
3 US sites in 3 states.
RecruitingNCT07843472
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Phase 3
Hoffmann-La Roche
About 2,500 people
Started Sep 30, 2026
In plain words A Phase 3 study of petrelintide in people 40 and older, run by Hoffmann-La Roche. It plans to enroll about 2,500 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 40 and older. Conditions: Obesity or Overweight; Cardiovascular Disease.
Participants with BMI ≥ 27 kg/m² and established CVD
History of at least one self-reported unsuccessful dietary effort to lose body weight
The exclusion criteria are on the listing.
What it tests, as registered
Petrelintide; Placebo
Registered summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Where, as registered
3 US sites in 3 states.
RecruitingNCT07843485
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Phase 3
Hoffmann-La Roche
About 600 people
Starts Sep 30, 2026 (estimated)
In plain words A Phase 3 study of petrelintide in people 18 and older, run by Hoffmann-La Roche. It plans to enroll about 600 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity or Overweight; Type 2 Diabetes.
Participants with BMI ≥ 27 kg/m²
T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening
Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening
History of at least one self-reported unsuccessful dietary effort to lose body weight
The exclusion criteria are on the listing.
What it tests, as registered
Petrelintide; Placebo
Registered summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Where, as registered
2 US sites in 2 states.
RecruitingNCT06951854
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
Phase 2
Neuroventi Inc.
About 105 people
Started Apr 1, 2025
In plain words A Phase 2 study of petrelintide in people 6 to 15, run by Neuroventi Inc.. It plans to enroll about 105 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 15. Conditions: Autism Spectrum Disorder (ASD.
Persistent deficits in social communication and social interaction across multiple contexts, as manifested by all of the following:
The exclusion criteria are on the listing.
What it tests, as registered
Drug: NV01-A02; Drug: Placebo (ZP8396)
Registered summary
This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum Disorder (ASD).
Where, as registered
No US site; South Korea (1).
RecruitingNCT07682818
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
Phase 1
Zealand Pharma
About 36 people
Started May 18, 2026
In plain words A Phase 1 study of petrelintide in people 18 to 70, run by Zealand Pharma. It plans to enroll about 36 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70; healthy volunteers accepted. Conditions: Impaired Hepatic Function.
Sex: male and female participants.
Body mass index (BMI): 18.5 to 40.0 kg/m\^2, inclusive, at screening.
Participants who are considered healthy as determined by medical history, physical examination, and other screening procedures, with clinically normal hepatic function at screening..
Clinical laboratory test results within normal reference range for the population, or results with acceptable deviations that are judged not to be clinically significant by the Investigator.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Petrelintide
Registered summary
This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities. The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.
Where, as registered
No US site; Slovakia (2), Poland (1).
Not yet recruitingNCT07589686
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
Phase 2
Hoffmann-La Roche
About 486 people
Starts Sep 30, 2026 (estimated)
In plain words A Phase 2 study of petrelintide in people 18 and older, run by Hoffmann-La Roche. It plans to enroll about 486 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity or Overweight.
Male or female participants with Body Mass Index (BMI) ≥ 30 kg/m² OR BMI ≥ 27 kg/m² to < 30 kg/m² with at least one weight-related comorbidity
History of at least one self-reported unsuccessful dietary effort to lose body weight
HbA1c ≥ 48 mmol/mol (6.5%) at screening
History of Type 1 or Type 2 Diabetes
12 more inclusion criteria and the exclusion criteria are on the listing.
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.